The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's ...

Recent health news highlights a 10% rise in child TB infections in Europe, detected mammal bird flu cases, and economic ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

The prescribed dosage for Nucala (mepolizumab) may vary depending on a person’s individual treatment plan, specific diagnosis, and age. Typically, Nucala is given once every 4 weeks as a ...

As with other drugs, Nucala (mepolizumab) can cause side effects, such as headache and joint pain. If you are not able to tolerate side effects of Nucala, talk with your doctor or pharmacist.

GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking approval for a new indication of its respiratory drug, Nucala (mepolizumab).

Nucala (mepolizumab) is a prescription drug used to treat a certain kind of asthma and some other immune-related conditions. The drug is typically given once every 4 weeks as an injection under ...

Current health news highlights a 10% rise in child TB infections in Europe, a new drug review by European regulators, the ...

GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...

March 24 (Reuters) - GSK (GSK.L), opens new tab on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's asthama drug Nucala as an ...